anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The normal functioning of every cell in the body depends on its bioelectric properties and many diseases are caused by genetic and/or epigenetic dysregulation of the underlying ion channels. Metastasis, the main cause of death from cancer, is a complex multi-stage process in which cells break away from a primary tumour, invade the surrounding tissues, enter the circulation by encountering a blood vessel and spread around the body, ultimately lodging in distant organs and reproliferating to form secondary tumours leading to devastating organ failure. Such cellular behaviours are well known to involve ion channels. The CELEX model offers a novel insight to metastasis where it is the electrical excitation of the cancer cells that is responsible for their aggressive and invasive behaviour. In turn, the hyperexcitability is underpinned by concomitant upregulation of functional voltage-gated sodium channels and downregulation of voltage-gated potassium channels. Here, we update the in vitro and in vivo evidence in favour of the CELEX model for carcinomas. The results are unequivocal for the sodium channel. The potassium channel arm is also broadly supported by existing evidence although these data are complicated by the impact of the channels on the membrane potential and consequent secondary effects. Finally, consistent with the CELEX model, we show (i) that carcinomas are indeed electrically excitable and capable of generating action potentials and (ii) that combination of a sodium channel inhibitor and a potassium channel opener can produce a strong, additive anti-invasive effect. We discuss the possible clinical implications of the CELEX model in managing cancer.
Clinical studies of Asacol did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy in elderly patients should be considered when prescribing Asacol. Reports from uncontrolled clinical studies and post-marketing reporting systems suggest a higher incidence of blood dyscrasias, i.e., agranulocytosis, neutropenia, pancytopenia, in subjects receiving Asacol who are 65 years or older. Caution should be taken to closely monitor blood cell counts during drug therapy.

This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken when prescribing this drug therapy. As stated in the PRECAUTIONS section, it is recommended that all patients have an evaluation of renal function prior to initiation of Asacol tablets and periodically while on Asacol therapy.
The final phase of the study aims to identify if the addition of technical assistance to the current course not only impacts knowledge of participants but also their self-reported engagement in skills that are outputs of their knowledge acquisition. Additionally, the third phase will link participation in the course and TA (technical assistance) to employment outcomes of individuals with ID/DD (individuals with intellectual and/or developmental disability). These additions address large gaps in the extant literature and research on employment specialists, training, and its impact on employment outcomes.

While, evidence-based practices in SE (Supported Employment) exist, research indicates that these practices are not often put into practice. Furthermore, of the few studies that have explored ES(Employment Specialist) training and its effectiveness, very few have identified if training impacts the employment outcomes of individuals with disabilities. Employment specialists and their skill directly impact the successful employment of individuals with ID/DD. Despite the introduction of SE into the field over four decades ago as well as legislative support, employment outcomes of individuals with remain dismally low. It is necessary to begin to gather evidence of the impact of training as well as feasibility and dosage in order to identify how to prepare employment service providers to better support individuals with disabilities to access employment.
One family member of each patient will be involved during all 12 CBGT sessions. The CBGT program that will be employed in the present study is a protocoled therapy consisting of psychoeducation, ERP techniques, cognitive tools to change dysfunctional thoughts and beliefs, strategies to prevent relapses, discussion on the family involvement (e.g. FA, burden, ...) and homework exercises after each session.
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) has been reported in patients taking NSAIDs such as Orphengesic Forte Tablets. Some of these events have been fatal or life-threatening. DRESS typically, although not exclusively, presents with fever, rash, lymphadenopathy, and/or facial swelling. Other clinical manifestations may include hepatitis, nephritis, hematological abnormalities, myocarditis, or myositis. Sometimes symptoms of DRESS may resemble an acute viral infection. Eosinophilia is often present. Because this disorder is variable in its presentation, other organ systems not noted here may be involved. It is important to note that early manifestations of hypersensitivity, such as fever or lymphadenopathy, may be present even though rash is not evident. If such signs or symptoms are present, discontinue Orphengesic Forte Tablets and evaluate the patient immediately.
Ischemic stroke, caused by diminished or interrupted cerebral blood flow, triggers the activation of microglial cells and subsequent inflammatory responses. Formononetin (FMN) has been observed to inhibit BV2 microglial cell activation and alleviate ensuing neuroinflammatory reactions. Despite extensive research, the precise underlying mechanism remains unclear. To investigate the neuroinflammatory response following FMN-mediated inhibition of BV2 microglial activation, we employed an in vitro oxygen-glucose deprivation/reperfusion (OGD/R) model. BV2 microglial cells were categorized into four groups: control, FMN, OGD/R, and OGD/R+FMN. Cell viability was assessed using the CCK-8 assay, while flow cytometry assessed M1 and M2 cell populations within BV2 cells. Immunofluorescence was utilized to detect the expression levels of apoptosis-inducing factor (AIF), p53, Toll-like receptor 4 (TLR4), and NF-κB p65. Western blotting (WB) was conducted to quantify p65/p-p65, IκB-α/p-IκB-α, and TLR4 protein levels in each group. Additionally, ELISA was employed to measure IL-1β and TNF-α levels in cell supernatants from each group. The results revealed a significant increase in the proportion of iNOS/CD206-positive M1/M2 cells in the OGD/R group compared to the control group (p < 0.05). There was also a notable increase in nuclear translocation of NF-κB p65 and elevated expression of inflammatory factors IL-1β and TNF-α in cell supernatants. Moreover, levels of p-p65, p-IκB-α, and TLR4 proteins were significantly elevated in the OGD/R group (p < 0.05). However, the addition of FMN reversed these effects. Specifically, FMN administration notably attenuated cell death and inflammation in BV2 microglia induced by OGD/R through modulation of the TLR4/NF-κB signaling pathway.These findings suggest that FMN may serve as a potential therapeutic agent against neuroinflammation associated with ischemic stroke by targeting microglial activation pathways.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to transplantology, and can be used to determine early dysfunction of the reticuloendothelial system (RES) of the liver in patients following orthotopic transplantation with no signs of graft dysfunction and manifested cytolysis by biochemical data. In patients with LDH, AST, ALT, bilirubin exceeding the upper limit of normal values by no more than 15–20 %, tacrolimus concentration in peripheral blood is determined. Whole body and liver are scanned in anterior and posterior projections 20–30 min after single administration ofTc-Technephyt. Total pulse count of the whole body and a mean hepatic count are determined. Obtained parameters are used to determine specific capture ofTc-Technephyt by liver from whole body pulse counting taking into account tacrolimus concentration in a specific patient by formula: SCH= (H/B+ H/B) × 5000 + K × Tc, where His the average count of liver pulses on the scintigram in the anterior projection, B- total count of whole body pulses on a scintigram in a front projection, H- average count of liver pulses on a scintigram in a posterior projection, Bis the total count of whole body pulses on the scintigram in the posterior projection, Tc is tacrolimus concentration in the peripheral blood, ng/ml, K = 0.09 is the experimentally calculated coefficient taking into accountTc-Technephyt capture by the transplanted liver with no immunosuppressive therapy. If observing values 1.63 ≤ SCH ≤ 1.83, the conclusion is made on the absence of RES transplant dysfunction. When obtaining the SCHvalues of beyond the specified confidence interval, a conclusion is made on early dysfunction of the RES transplant.EFFECT: method provides early diagnosis of transplant dysfunction by evaluating the accumulation of a radiopharmaceutical in the reticuloendothelial cells of the liver taking into account the concentration of tacrolimus or its analogues in the patient's peripheral blood.1 cl, 7 tbl, 4 ex
A protein hydrolysate composition is provided. The protein hydrolysate composition comprises isolated peptides useful for ameliorating a condition of a subject. Compositions comprising the protein hydrolysate composition are also provided. The compositions may be adapted for oral or topical administration to the subject, and may compose a foodstuff or beverage (e.g. a medical food), a topical composition (e.g. a lotion, cream, etc.), a kit, and the like. A methods of ameliorating the condition of the subject is further provided. The method include administering the protein hydrolysate composition to the subject. The method may be useful in reducing blood pressure, inflammation, reduced immunity, and/or oxidative stress in the subject.
The present invention relates to a pharmaceutical composition, a functional health food, and a feed composition, for innate immune-boosting and antiviral purposes, containing a Chelidonium majus L. extract as an active ingredient. The present invention further relates to a method for boosting innate immunity and increasing antiviral activities in animals, including a step of injecting the Chelidonium majus L. extract into animals requiring enhancement of innate immunity, not including human. According to the present invention, the Chelidonium majus L. composition for innate immune-boosting and antiviral purposes shows effectiveness in boosting innate immunity and antiviral activities, and thus the composition can be used for preventing and treating infectious disease caused by bacteria and virus. In addition, the Chelidonium majus L. composition can be widely used as drugs or functional health foods for boosting and regulating immunity in a patient with weakened or suppressed immunity, and also as feeds for innate immune-boosting and antiviral purposes for strengthening an anti-disease immune system in animals. Furthermore, the composition for innate immune-boosting and antiviral purposes, according to the present invention, barely causes toxicity or side effects. Thus, the composition can be used with ease even for a long period of time in order to prevent disease.
Participants will receive TENS and infrared treatment for 25 minutes, 5 days a week. Then Connective Tissue Massage will be applied.
The invention discloses an oral cavity external preparation. The preparation is a composite film composed of a back bottom layer, a slow-release layer and a quick-release layer. The back bottom layer is a film prepared from ethyl cellulose. The slow-release layer is a film prepared from mixed glue formed by mixing traditional Chinese medicine extracts, porous starch, chitosan, sodium alginate, polyving acohol, borneol, honey and purified water according to a certain mass ratio. The quick-release layer is a film prepared from mixed glue formed by mixing traditional Chinese medicine extracts, porous starch, borax, carbomer, peppermint oil and purified water according to a mass ratio. Meanwhile, the invention further discloses a preparation method of the preparation. By means of the unique formula of the traditional Chinese medicine extracts and scientific design of the dosage form film layers, troubles of existing oral cavity preparations are effectively solved, and the oral cavity external preparation takes effect quickly, is good in slow-release performance, has the effects of relieving swelling and pain and dispersing blood stasis and dredging collaterals and has the unique treatment effect of treating both symptoms and causes of periodontal diseases.
BACKGROUND: In 2021, China had a population of 264·01 million individuals over the age of 60, indicating a high prevalence of chronic diseases. Among older adults, physical inactivity (PI) is a significant risk factor for chronic diseases. However, few studies have been conducted on the correlation of physical activity (PA) with the economic status, geography and chronic disease risks in Chinese elderly. The objectives of this study were to better understand the distribution of PA among older adults in China and its relationship with economic status, geography, and chronic disease risks.
METHODS: This study utilized data from the China Longitudinal Aging Social Survey (CLASS) in 2020, post-COVID-19. The study employed a stratified, multistage, probabilistic sampling approach and included 11,396 adults over the age of 59 from 28 provinces in China. Data on demographics, the duration and intensity of PA, history of diseases and personalized factors influencing PA were collected via structured interviews by researchers. In this study, we conducted a comprehensive analysis, employing a range of statistical methods including descriptive analysis, Wilcoxon rank-sum tests, Bayesian networks, and chi-square tests.
RESULTS: The prevalence of PI among older adults over 59 in China is 28·82%. Significant regional differences were observed in the duration of PA at different intensities. Older adults residing in more economically developed areas were more likely to engage in moderate-to-vigorous physical activity (MVPA) and exhibited longer sedentary behavior. Economic status and urban-rural disparities consistently emerged as direct influential factors across all intensity types. Chronic disease risks were significantly lower in active older adults compared to inactive ones. Lack of social guidance, family support, and personal inclination towards sedentary behavior were the main personalized factors affecting PA among older adults, and these factors could be relatively easily modified.
CONCLUSIONS: Economic status, geography, and living areas (urban and rural) significantly influenced the distribution of physical activities in China. Particularly, economic status and living areas acted as direct factors. Older adults reaching the recommended standards for PA had significantly lower chronic disease risks, highlighting the importance of improving personalized factors which are crucial for promoting PA.
FIELD: medicine. ^ SUBSTANCE: there is described new avirulent isolate Lawsonia intracellularis. The isolate can be used for producing a based vaccine for the L. intracellularis infection. Also, there are disclosed methods for producing such vaccines, diagnosing the disease and producing an antiserum with using the isolate. ^ EFFECT: invention can be used in veterinary science. ^ 22 cl, 10 tbl, 3 ex
A theranostic agent can be used in both photoacoustic imaging (PAI) and photothermal therapy (PTT) applications. The theranostic agent can include a small molecule, organic compound with absorption in the near-infrared (NIR) interrogation window (700-900 nm). The compound can be a biocompatible organic nanoparticle (ONP). The theranostic agent can be effectively used in PAI and PAI-guided PTT applications. The theranostic agent can be administered to a patient to locate a tumor site in the patient using in vivo imaging techniques. Once the tumor site has been determined, the tumor site can be irradiated with near-infrared light to stop or inhibit the growth of the tumor.
A request distribution unit, an SO acquisition request reception unit, a creation request issuance unit, and an authorization unit are added to the clinical-path management server. The request distribution unit distributes an SO acquisition request and an access request for access to a CP. The SO acquisition request reception unit receives an SO acquisition request from a patient terminal. The creation request issuance unit issues an SO creation request to an SO attending doctor responsible for an SO. When the creation request is issued, the authorization unit grants editing authority to edit the CP of the patient requesting the SO. The authorization unit grants editing authority by updating authority management information stored in an authority management information storage unit.
Patients should also apply ciclopirox 8% nail polish in the first month of treatment every other day (day in and day out). In the second month applied twice a week. In the third month applied once a week. Apply on the affected nails, previously sanded. On the application of two products, Ciclopirox should be applied between the investigational product applications, e.g., in the middle of the day and the investigational product at the beginning and end of the day in the sun.
The purpose of this study is to improve the efficiency of treatment for post-traumatic stress disorder (PTSD) with prolonged exposure (PE), an efficacious treatment for PTSD typically administered in once- or twice-weekly sessions. We will evaluate whether massing 10 PE sessions in 2 weeks (massed trials; M-PE) is more efficacious than Minimal Contact control (MCC); 2) whether the massed sessions format retains the efficacy of treatment compared to 10 PE sessions spaced over 8 weeks (spaced trials; S-PE), and 3) will evaluate for the first time the efficacy of the 10 PE sessions delivered in 8 weeks in an active duty population by comparing it to an active comparison condition, Present-Centered Therapy (PCT). Randomization was initially set at 3:11:11:11 for MCC:M-PE:S-PE:PCT. Due to the urgent need for data to inform military clinical practice, enrollment in MCC was accelerated by changing the ratio to 1:1:1:1 in order to report the comparison between M-PE and MCC. When 30 participants were enrolled in MCC, randomization resumed to approximately 3:11:11:11. Prolonged Exposure (PE; Foa, Hembree, \& Rothbaum, 2007; Foa \& Rothbaum, 1998) was developed by the PI, Edna Foa, and colleagues in the Center for the Treatment \& Study of Anxiety (CTSA), University of Pennsylvania. It has been found quite efficacious in reducing PTSD and related psychopathology with various types of trauma in PTSD centers around the world. Furthermore, PE has been identified in the joint VA-Department of Defense Clinical Practice Guideline for PTSD (VA-DoD Clinical Practice Guideline Working Group, 2003) as "strongly recommended" for use with veterans with PTSD, based on the strong empirical support for PE.

This study is part of the South Texas Research Organizational Network Guiding Studies on Trauma and Resilience (STRONG STAR) (Consortium Director: Alan L. Peterson, Ph.D., ABPP, Professor, Behavioral Wellness Center for Clinical Trials, Department of Psychiatry-Mail Code 7792, University of Texas Health Science Center at San Antonio (UTHSCSA), 7703 Floyd Curl Drive, San Antonio, TX 78229-3900). Dr. Edna Foa is the overall PI of the study, and the on-site PI is COL Jeffrey Yarvis, Ph.D.,Chief, Soldier Behavioral Health/Outpatient Psychiatry, Carl R. Darnall Army Medical Center, 36000 Darnall Loop, Fort Hood, TX, 76544. The study will be conducted at Fort Hood, Texas.
The nuclear factor binding the κ light chain in B-cells (NFκB) is involved in a wide range of cellular processes including development, growth, innate immunity, and sleep. However, genetic studies of the role of specific NFκB transcription factors in sleep have been limited. Drosophila fruit flies carry three genes encoding NFκB transcription factors, Dorsal, Dorsal Immunity Factor (Dif), and Relish. We previously found that loss of the Relish gene from fat body suppressed daily nighttime sleep, and abolished infection-induced sleep. Here we show that Dif regulates daily sleep and recovery sleep following prolonged wakefulness. Mutants of Dif showed reduced daily sleep and suppressed recovery in response to sleep deprivation. Pan-neuronal knockdown of Dif strongly suppressed daily sleep, indicating that in contrast to Relish, Dif functions from the central nervous system to regulate sleep. Based on the unique expression pattern of a Dif- GAL4 driver, we hypothesized that its effects on sleep were mediated by the pars intercerebralis (PI). While RNAi knock-down of Dif in the PI reduced daily sleep, it had no effect on the recovery response to sleep deprivation. However, recovery sleep was suppressed when RNAi knock-down of Dif was distributed across a wider range of neurons. Induction of the nemuri (nur) antimicrobial peptide by sleep deprivation was reduced in Dif mutants and pan-neuronal overexpression of nur also suppressed the Dif mutant phenotype by significantly increasing sleep and reducing nighttime arousability. Together, these findings indicate that Dif functions from brain to target nemuri and to promote deep sleep.